Twist Bioscience Corporation

Equities

TWST

US90184D1000

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
34.31 USD -0.49% Intraday chart for Twist Bioscience Corporation -4.77% -6.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Twist Bioscience Corporation Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations CI
Transcript : Twist Bioscience Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
Twist Bioscience Corporation Launches IVDR-Compliant Precision Dx Products for Whole Exome Sequencing CI
Twist Bioscience Announces Partnership With Element Biosciences, Launches Liquid Biopsy Kit MT
Twist Bioscience Corporation and Element Biosciences, Inc. Announce Collaboration to Develop Twist for Element, Exome 2.0 Plus Comprehensive Exome Spike-In Workflow for Element?s AVITI System CI
Twist Bioscience Corporation Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications CI
Scotiabank Adjusts Twist Bioscience's Price Target to $43 From $30, Maintains Sector Outperform Rating MT
Twist Bioscience Corporation Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT CI
Sector Update: Health Care Stocks Steady Premarket Friday MT
Twist Bioscience's Fiscal Q1 Net Loss Widens, Revenue Rises; Fiscal 2024 Revenue Guidance Lifted MT
Transcript : Twist Bioscience Corporation, Q1 2024 Earnings Call, Feb 02, 2024
Earnings Flash (TWST) TWIST BIOSCIENCE CORPORATION Reports Q1 Revenue $71.5M, vs. Street Est of $67.6M MT
Twist Bioscience Corporation Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024 CI
Twist Bioscience Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024 CI
North American Morning Briefing : Jobs Report Tops -2- DJ
Barclays Raises Price Target on Twist Bioscience to $45 From $30, Keeps Overweight Rating MT
Twist Bioscience Corporation Expands Express Genes Rapid Synthesis Service CI
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Raises Price Target to $45 From $25 MT
North American Morning Briefing : TSMC Results -2- DJ
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Price Target is $45 MT
Transcript : Twist Bioscience Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 05:15 PM
Twist Bioscience Names Adam Laponis Chief Financial Officer MT
Twist Bioscience Corporation Appoints Adam Laponis as Principal Financial Officer, Effective January 8, 2024 CI
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer CI
Chart Twist Bioscience Corporation
More charts
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
34.31 USD
Average target price
39 USD
Spread / Average Target
+13.67%
Consensus